Literature DB >> 18484903

Editor's perspective on metabolic syndrome for 2008.

I Jialal.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18484903      PMCID： PMC2696398          DOI： 10.1089/met.2008.ED.08

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN： 1540-4196            Impact factor:   1.894


× No keyword cloud information.
  9 in total

Review 1.  Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.

Authors:  Scott M Grundy
Journal:  Nat Rev Drug Discov       Date:  2006-04       Impact factor: 84.694

2.  Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Authors:  I Jialal; D Stein; D Balis; S M Grundy; B Adams-Huet; S Devaraj
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

3.  Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes.

Authors:  Franklin J Zieve; Marcia F Kalin; Sherwyn L Schwartz; Michael R Jones; William L Bailey
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

4.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

5.  Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Authors:  Prakash Deedwania; Philip Barter; Rafael Carmena; Jean-Charles Fruchart; Scott M Grundy; Steven Haffner; John J P Kastelein; John C LaRosa; Holly Schachner; James Shepherd; David D Waters
Journal:  Lancet       Date:  2006-09-09       Impact factor: 79.321

6.  Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.

Authors:  Sridevi Devaraj; Emily Chan; Ishwarlal Jialal
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

7.  The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.

Authors:  T P Didangelos; A K Thanopoulou; S H Bousboulas; C L Sambanis; V G Athyros; E A Spanou; K C Dimitriou; S I Pappas; B G Karamanos; D T Karamitsos
Journal:  Curr Med Res Opin       Date:  2004-09       Impact factor: 2.580

Review 8.  Treating the metabolic syndrome.

Authors:  Cristina Bianchi; Giuseppe Penno; Fabiola Romero; Stefano Del Prato; Roberto Miccoli
Journal:  Expert Rev Cardiovasc Ther       Date:  2007-05

9.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

Authors:  F Xavier Pi-Sunyer; Louis J Aronne; Hassan M Heshmati; Jeanne Devin; Julio Rosenstock
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.